Abstract
Although platelets lack nuclei, they are capable of de novo protein synthesis. We speculate that key platelet receptors are involved in the regulation of this process, and the changes in their number indicate the de novo protein synthesis in platelets. The object of our study was native platelets obtained from healthy donors. Using flow cytometry and Western blot, we determined the number of GP IIb-IIIa receptors (fibrinogen receptor) and P2Y12 receptors (ADP receptor) on the surface of platelets upon their activation with ADP and collagen. To verify the approaches and techniques used, we studied IL-1β protein, which was previously shown to be synthesized de novo in activated platelets. GP IIb-IIIa receptor numbers correlate with the number of P2Y12 receptors on the cell surface (R = 0.45, p = 0.03). It was demonstrated that the platelet receptor numbers are higher on the surface of the cells with high functional activity. According to the data obtained by Western blot, upon the cell activation with ADP, the number of GP IIb-IIIa and P2Y12 receptors increases, which may serve as evidence of these proteins being synthesized in the activated platelets. It was observed that the level of P2Y12 and IL-1β was lower in the samples where GP IIb-IIIa receptor was blocked by the selective inhibitor, i.e., the Fab fragment of the antibodies that specifically recognizes the GP IIb-IIIa complex. This suggests the important role of GP IIb-IIIa receptor in the regulation of protein synthesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ADP:
-
adenosine diphosphate
- PRP:
-
platelet rich plasma
- MFI:
-
mean fluorescence intensity
- RGD repeats:
-
tripeptides consisting of arginine, glycine, and aspartic acid residues
References
Warshaw A.L., Laster L., Shulman N.R. 1966. The stimulation by thrombin of glucose oxidation in human platelets. J. Clin. Invest. 45, 1923–1934.
Warshaw A.L., Laster L., Shulman N.R. 1967. Protein synthesis by human platelets. J. Biol. Chem. 242, 2094–2097.
Kieffer N., Guichard J., Farcet J.P., Vainchenker W., Breton-Gorius J. 1987. Biosynthesis of major platelet proteins in human blood platelets. Eur. J. Biochem. 164, 189–195.
Schwertz H., Tolley N.O., Foulks J.M., Denis M.M., Risenmay B.W., Buerke M., Tilley R.E., Rondina M.T., Harris E.M., Kraiss L.W., Mackman N., Zimmerman G.A., Weyrich A.S. 2006. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets. J. Exp. Med. 203, 2433–2440.
Brogren H., Karlsson L., Andersson M., Wang L., Erlinge D., Jern S. 2004. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood. 104, 3943–3948.
Pabla R., Weyrich A.S., Dixon D.A., Bray P.F., McIntyre T.M., Prescott S.M., Zimmerman G.A. 1999. Integrin-dependent control of translation: Engagement of integrin alpha IIb beta3 regulates synthesis of proteins in activated human platelets. J. Cell. Biol. 144, 175–184.
Born G.V.R. 1962. Quantitative investigations into aggregation of blood platelets. J. Physiol. 162, 67–68.
Born G.V.R. 1964. Aggregation of platelet by adenosine diphosphate and its reversal. Nature. 194, 927–929.
O’Brien D.K., Heywood J.B., Heady J.A. 1966. The quantitation of platelet aggregation induced by four compounds: A study relation to myocardial infarction. Thromb. Haemorrh. 16, 725–767.
Sirotkina O.V., Bogan’kova N.A., Laskovets A.B., Kukharchik G.A., Gaikovaya L.B., Vavilova T. V. Immunological methods for assessing platelet functional activity in patients with cardiovascular disases. Med. Immunol. 12, 213–218.
Sirotkina O.V., Vavilova T.V. 2012. An algorithm of molecular genetic analysis for individual sensitivity to antiaggregant drugs: A step toward persomalized medicine. Aterotromboz. 1, 49–55.
Byzova T.V., Vlasik T.N., Mazurov A.V. 1994. Inhibition of platelet aggregation by monoclonal antibodies to the IIb–IIIa glycoprotein complex. Byull. Eksp. Biol. Med. 118, 402–405.
Mazurov A.V., Khaspekova S.G., Byzova T.V., Tikhomirov O.Yu., Berndt M.C., Steiner B., Kouns W.C. 1996. Stimulation of platelet glycoprotein IIb–IIIa (IIb 3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa. FEBS Lett. 391, 84–88.
Sambrook J., Fritsch E.F., Maniatis T. 1989). Molecular Cloning. A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press, vol. 3, pp. 18.47–18.77.
Thon J.N., Devine D.V. 2007. Translation of glycoprotein IIIa in stored blood platelets. Transfusion. 47, 2260–2270.
Michelson A.D., Barnard M.R. 1987. Thrombininduced changes in platelet membrane glycoproteins Ib, IX,and IIb–IIIa complex. Blood. 70, 1673–1678.
Haberstock-Debic H., Andre P., Mills S., Phillips D.R., Conley P.B. 2011. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. J. Pharmacol. Exp. Ther. 339, 54–61.
Denis M.M., Tolley N.D., Bunting M., Schwertz H., Jiang H., Lindemann S., Yost C.C., Rubner F.J., Albertine K.H., Swoboda K.J., Fratto C.M., Tolley E., Kraiss L.W., McIntyre T.M., Zimmerman G.A., Weyrich A.S. 2005. Escaping the nuclear confines: Signaldependent pre-mRNA splicing in anucleate platelets. Cell. 122, 379–391.
Evangelista V., Manarini S., Di Santo A., Capone M.L., Ricciotti E., Di Francesco L., Tacconelli S., Sacchetti A, D’Angelo S., Scilimati A., Sciulli M.G., Patrignani P. 2006. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ. Res. 98, 593–595.
Booyse F.M., Rafelson M.E. 1967. Stable messenger RNA in the synthesis of contractile protein in human platelets. Biochim. Biophys. Acta. 145, 188–190.
Zimmerman G.A., Weyrich A.S. 2008. Signal-dependent protein synthesis by activated platelets. Arterioscler. Thromb. Vasc. Biol. 28, s17–s24.
Mazurov A.V., Pevzner D.V., Vlasik T.N., Ruda M.Ya. 2004. Antiplatelet effects of glycoproteins IIb-IIIa antagonist monafram. Ross. Fiziol. Zh. 90, 586–599.
Sulimov V.A. 2008. Antithrombotic therapy during transcutaneous coronary interventions. Ratsional. Farmakoter. Kardiol. 3, 91–100.
Hashemzadeh M., Furukawa M., Goldsberry S., Movahed M. R. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review. 2008. Exp. Clin. Cardiol. 13, 192–197.
Weyrich A., Schwertz H., Kraiss L.W., Zimmerman G.A. 2009. Protein synthesis by platelets: Historical and new perspectives. J. Thromb. Haemost. 7, 241–246.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © O.V. Sirotkina, A.B. Laskovets, P.A. Andoskin, A.K. Emelyanov, A.M. Zabotina, T.V. Vavilova, 2016, published in Molekulyarnaya Biologiya, 2016, Vol. 50, No. 1, pp. 128–135.
Rights and permissions
About this article
Cite this article
Sirotkina, O.V., Laskovets, A.B., Andoskin, P.A. et al. Increase in GP IIb-IIIa and P2Y12 receptors in activated platelets as the possible indicator of de novo protein synthesis. Mol Biol 50, 111–117 (2016). https://doi.org/10.1134/S0026893316010180
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893316010180